Expertise in
28
conditions

Dr. Ghassan M. Al-Jazayrly

Hematology Oncology | Hematology | Oncology
1300 N Vermont Ave, Suite 606, 
Los Angeles, CA 
Expertise in
28
conditions
1300 N Vermont Ave, Suite 606, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ghassan Al-Jazayrly is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Al-Jazayrly is highly rated in 28 conditions, according to our data. His top areas of expertise are Anemia, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Lung Cancer.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Hollywood Presbyterian Medical Center
Glendale Mem Hospital & Hlth Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Scan Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

1300 N Vermont Ave, Suite 606, Los Angeles, CA 90027
Other Locations
COMPLETE CARE COMMUNITY HEALTH CENTER, INC
2928 E Cesar E Chavez Ave, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer
Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer
Enrollment Status: Unknown
Publish Date: February 09, 2022
Intervention Type: Drug
Study Drugs: Gedatolisib, Faslodex, Palbociclib, Zoladex
Study Phase: Phase 1
View 6 Less Clinical Trials
Similar Doctors
Expertise in
26
conditions
Dr. Sant P. Chawla
Hematology | Oncology | Pain Medicine
Expertise in
26
conditions
Dr. Sant P. Chawla
Hematology | Oncology | Pain Medicine
2811 Wilshire Blvd, Suite 414, 
Santa Monica, CA 
 (11.3 mi)
310-552-9999
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is highly rated in 26 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma.

Expertise in
18
conditions
Dr. Tycel J. Phillips
Hematology | Hematology Oncology | Oncology
Expertise in
18
conditions
Dr. Tycel J. Phillips
Hematology | Hematology Oncology | Oncology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (8.2 mi)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tycel Phillips is a Hematologist and a Hematologist Oncology provider in South Pasadena, California. Dr. Phillips is highly rated in 18 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
15
conditions
Dr. Alexey V. Danilov
Hematology | Hematology Oncology | Oncology
Expertise in
15
conditions
Dr. Alexey V. Danilov
Hematology | Hematology Oncology | Oncology

City Of Hope Medical Foundation

1500 E Duarte Rd, 
Duarte, CA 
 (18.3 mi)
Languages Spoken:
English
Offers Telehealth

Alexey Danilov is a Hematologist and a Hematologist Oncology provider in Duarte, California. Dr. Danilov is highly rated in 15 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Al-Jazayrly's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 118 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile